Angiovac
Payments companies reported to CMS as associated with Angiovac. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Angiovac, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Angiovac
These are the largest totals companies reported as associated with Angiovac. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| John Moriarty | Los Angeles, CA | Vascular & Interventional Radiology | $116,012.76 |
| Kenneth Rosenfield | Boston, MA | Cardiovascular Disease | $81,884.51 |
| David Zlotnick | Buffalo, NY | Interventional Cardiology | $69,334.57 |
| V Reddy | Nashville, TN | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $61,938.32 |
| Sabah Butty | Mishawaka, IN | Vascular & Interventional Radiology | $48,810.03 |
| Maximilian Pyko | Indianapolis, IN | Vascular & Interventional Radiology | $20,528.30 |
| Marquand Patton | Miami, FL | Interventional Cardiology | $20,429.17 |
| Stephanie Younes | Toledo, OH | Interventional Cardiology | $15,354.99 |
| Jason Yoho | Seguin, TX | Interventional Cardiology | $12,780.60 |
| John Rundback | Teaneck, NJ | Vascular & Interventional Radiology | $8,877.75 |
Prescribed Angiovac?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.